My group focuses on immunological approaches to the treatment of haematological cancers. In particular, we are interested in understanding: The molecular mechanisms whereby cancer cells induce changes in the host immune system; the use of allogeneic stem cell bone marrow transplant to induce a graft versus leukaemia effect; identification of the antigenic targets expressed by cancer cells; and the use of agents that will make tumour cells more susceptible to immune cell mediated killing, without impacting on the host immune system.
Expression of FOXP3, CD68 and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma is Predictive of outcome. J Clin Oncol (2013) 31(2):256-62. PMID: 23045593
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA (2009) 106(15):6250-5. PMID: 19332800
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 118(7):2427-37. PMID: 18551193
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood (2008) 112(2):394-7. PMID: 18434611
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Flinn IW, Gribben JG, Dyer MJS et al. Blood (2019) 133(2) 2765-2775
Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Araf S, Wang J, Korfi K et al. Leukemia (2019) 33(2) 1540
Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Gruber M, Bozic I, Leshchiner I et al. Nature (2019) 570(2) 474-479
Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. Snowden JA, Hawkey C, Hind D et al. BMC Gastroenterol (2019) 19(2) 82
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Leonard JP, Trneny M, Izutsu K et al. J Clin Oncol (2019) 37(2) 1188-1199
Single cell analysis of clonal architecture in acute myeloid leukaemia. Potter N, Miraki-Moud F, Ermini L et al. Leukemia (2019) 33(2) 1113-1123
Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation. Sun D, Stopka-Farooqui U, Barry S et al. Cell Rep (2019) 27(2) 1461-1471.e4
Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma. Zhang T, Guan X-W, Gribben JG et al. Cell Death Dis (2019) 10(2) 330
Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. Baptista MJ, Tapia G, Morgades M et al. Leuk Lymphoma (2019) 60(2) 1087-1091
Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells. Goulart MR, Hlavaty SI, Chang Y-M et al. Sci Rep (2019) 9(2) 3574
Group Leaders in the Centre
Dr Andrejs Braun, Dr Pedro Cutillas, Dr Jeff Davies, Dr Gabriella Ficz, Professor Jude Fitzgibbon, Dr Li Jia, Professor Kamil R. Kranc, Dr Sergey Krysov, Dr Rifca Le Dieu, Dr Kevin Rouault-Pierre, Dr John Riches, Dr Bela Wrench
Clinical Research Fellows
Dr Jennifer Edelmann, Dr Robin Sanderson, Dr Joseph Taylor, Dr Edward Truelove
I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.
In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.